MCID: CHR079
MIFTS: 37

Choroid Disease

Categories: Eye diseases

Aliases & Classifications for Choroid Disease

MalaCards integrated aliases for Choroid Disease:

Name: Choroid Disease 12 15
Abnormality of the Choroid 30 6
Choroid Diseases 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1417
ICD9CM 36 363.9
MeSH 45 D015862
NCIt 51 C34468
ICD10 34 H31 H31.8 H31.9
UMLS 74 C0008521

Summaries for Choroid Disease

MalaCards based summary : Choroid Disease, also known as abnormality of the choroid, is related to choroideremia and x-linked recessive disease. An important gene associated with Choroid Disease is CHM (CHM Rab Escort Protein), and among its related pathways/superpathways are Metabolism of fat-soluble vitamins and RAB geranylgeranylation. The drugs Ranibizumab and Povidone-iodine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are nervous system and pigmentation

Wikipedia : 77 The choroid, also known as the choroidea or choroid coat, is the vascular layer of the eye, containing... more...

Related Diseases for Choroid Disease

Graphical network of the top 20 diseases related to Choroid Disease:



Diseases related to Choroid Disease

Symptoms & Phenotypes for Choroid Disease

MGI Mouse Phenotypes related to Choroid Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.81 CHM OAT POU3F4 RAB27A RBP3 RHO
2 pigmentation MP:0001186 9.43 CHM OAT RAB27A RHO RPE65 RPGR
3 vision/eye MP:0005391 9.23 CHM OAT RAB27A RBP3 RHO ROM1

Drugs & Therapeutics for Choroid Disease

Drugs for Choroid Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
2
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
5
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
6
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 129497-78-5
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
10
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
11
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Ofloxacin Approved Phase 4 82419-36-1 4583
14
Lactitol Investigational Phase 4,Not Applicable 585-86-4, 585-88-6 493591
15 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 cadexomer iodine Phase 4,Not Applicable
18 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
28 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
29
protease inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 BB 1101 Phase 4,Phase 3,Phase 2,Not Applicable
32 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1
37 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1
38 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
39 Adrenergic Antagonists Phase 4
40 Adrenergic alpha-1 Receptor Antagonists Phase 4
41 Neurotransmitter Agents Phase 4
42 Adrenergic alpha-Antagonists Phase 4
43 Adrenergic Agents Phase 4
44 Ophthalmic Solutions Phase 4,Phase 2
45 beta-endorphin Phase 4
46 Adrenocorticotropic Hormone Phase 4
47 Melanocyte-Stimulating Hormones Phase 4
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
49 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
2 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
3 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
4 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
5 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
6 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
7 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Completed NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
8 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Completed NCT02320474 Phase 4 Aflibercept
9 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
10 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
11 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
12 Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Completed NCT03393767 Phase 4 Ranibizumab
13 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
14 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
15 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
16 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
17 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
18 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
19 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
20 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
21 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
22 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
23 Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
24 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
25 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
26 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
27 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
28 Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Unknown status NCT00599820 Phase 3 Intravitreal Bevacizumab
29 Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Unknown status NCT00344617 Phase 3 Bevacizumab (tradename: Avastin)
30 Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia Unknown status NCT01716026 Phase 3 Bevazizumab intravitreal injection
31 A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV Unknown status NCT01809223 Phase 3 conbercept, Fixed;conbercept, PRN
32 A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Unknown status NCT00454389 Phase 3 ranibizumab
33 Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Unknown status NCT00157976 Phase 3 Photrex (rostaporfin)
34 Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization Unknown status NCT00930189 Phase 2, Phase 3 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone
35 Avastin for CNV Secondary to Pattern Dystrophy Unknown status NCT00391144 Phase 2, Phase 3
36 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
37 Efficacy of Retreatments With Intravitreal Bevacizumab Unknown status NCT00406744 Phase 3 Intravitreal injection of Bevacizumab
38 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
39 Macular Photocoagulation Study (MPS) Unknown status NCT00000158 Phase 3
40 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
41 Intravitreal Bevacizumab for Inflammatory Neovascular Membranes Completed NCT00407121 Phase 3 Bevacizumab
42 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
43 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
44 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
45 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
46 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Completed NCT01840410 Phase 3 Ranibizumab
47 Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Completed NCT00417833 Phase 2, Phase 3 Intravitreal Bevacizumab
48 Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV) Completed NCT00370786 Phase 3 bevacizumab
49 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
50 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin

Search NIH Clinical Center for Choroid Disease

Cochrane evidence based reviews: choroid diseases

Genetic Tests for Choroid Disease

Genetic tests related to Choroid Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Choroid 30

Anatomical Context for Choroid Disease

MalaCards organs/tissues related to Choroid Disease:

42
Eye, Retina, Endothelial, Testes

Publications for Choroid Disease

Variations for Choroid Disease

ClinVar genetic disease variations for Choroid Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh38 Chromosome 10, 124402952: 124402952
2 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh37 Chromosome 10, 126091521: 126091521

Expression for Choroid Disease

Search GEO for disease gene expression data for Choroid Disease.

Pathways for Choroid Disease

GO Terms for Choroid Disease

Cellular components related to Choroid Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment membrane GO:0042622 8.96 RHO ROM1
2 photoreceptor outer segment GO:0001750 8.8 RAB27A RHO RPGR

Biological processes related to Choroid Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.67 CHM RHO RPE65 RPGR
2 intracellular protein transport GO:0006886 9.63 CHM RAB27A RPGR
3 retina development in camera-type eye GO:0060041 9.43 RHO RPE65
4 cellular amino acid biosynthetic process GO:0008652 9.4 OAT PYCR1
5 response to light stimulus GO:0009416 9.32 RHO RPE65
6 retina morphogenesis in camera-type eye GO:0060042 9.26 ROM1 RPE65
7 visual perception GO:0007601 9.17 CHM OAT RBP3 RHO ROM1 RPE65
8 L-proline biosynthetic process GO:0055129 9.16 OAT PYCR1
9 retinoid metabolic process GO:0001523 9.13 RBP3 RHO RPE65

Sources for Choroid Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....